Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- Drug Discovery
- HIV / AIDs
- cell therapy
- Medical Info
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372479
And the grant is restated as
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
– exclusive for Products containing or based on any lentivirus vector including human and non-human lentivirus.
In addition, Licensor grants a nonexclusive license under the Patents in the Field and in the Territory to make or to have made by a Thirty Party Good Manufacturing Practice (GMP) batches of lentiviral vectors for its/their own clinical trials on Products, provided that such Third Party makes Good Manufacturing Practice (GMP) batches of lentiviral vectors solely for the Licensee and its Affiliates and sublicensees clinical trials of Products above mentioned.
Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species. The genus includes the human immunodeficiency virus, which causes AIDS.
IPSCIO Record ID: 372469
— exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
— non exclusive for Products containing non-human lentivirus vector.
Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.
IPSCIO Record ID: 372419
Gene therapy shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein or other molecule, in order to restore the functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) or molecule(s) not normally expressed in the cell type or expression of protein(s) or molecule(s) that do not exist normally in nature. The introduced protein(s) or molecule(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein or molecule encoded by the introduced DNA sequence of interest for use in Vaccination.
Chimeric antigen receptor cells is a special receptor created in the laboratory that is designed to bind to certain proteins on cancer cells. The chimeric antigen receptor is then added to immune cells called T cells.
IPSCIO Record ID: 372467
University grants to an exclusive, royalty-free commercial license to use, reproduce, modify, make derivatives of, and transfer the Tangible Property in conjunction with the Licensed Products and Licensed Processes or as otherwise necessary or useful for the exercise of the Patent Rights licensed hereunder.
University grants to a nonexclusive, non-royalty-bearing license to non-tangible know-how associated with the technology, and further agrees that this know-how may be transferred by Licensee to third parties.
— A Technique For The Treatment Of Human Genetic Disorders of Erythroid Cells;
— The cDNA of Heme-Regulated Eif-2 Alpha Kinase;
— Gene Transfer Of A Hybrid (Beta/Delta Or Al ha) Globin Gene, For The Gene Therapy Of Sickle Cell Anemia;
— Design And Optimization Of Retroviral Vectors Transducing Human Heta-Globin Gene And Locus
Control Region Derivatives;
— Gene Therapy Procedure Aimed At Inhibition of Tumor Angiogenesis;
— Integrative Non-Viral Vectors – Based On Retroviral Integrase;
— Nuclear Transport Of Type-C Retrovirus Based Vectors;
— LDL Receptor/ Alpha2-Macroglobulin Hybrid Gene; and,
— Mutant EEF-2 And 11-3 Hormonotoxin.
University is the co-owner of the Patent Rights for
— Integrative Non-Viral Vectors (Based on Site-Specific Recombination).
The amendment 1 of December 12, 2003 adds
— Therapeutic Lentiviral Vectors for Gene Therapy of Hemoglobinopathies; and,
— Therapeutic Lentiviral Vectors For Gene Therapy.
The hemoglobinopathies are a group of disorders passed down through families (inherited) in which there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells.
Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species.
IPSCIO Record ID: 230759
A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.
A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or, is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].
(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].
c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].
(d) All human [infectious diseases other than HIV]. This Field includes [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.
IPSCIO Record ID: 372471
Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.
Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement. Target Antigens will be limited to the oncology associated antigens designated.
T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.
Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.
CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patientâ€™s genetically modified cells are intended to bind to and kill the target cancer cells.
The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.
The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.
IPSCIO Record ID: 380356
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by a defect in the very long chain of fatty acids transporter in peroxisomes, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
IPSCIO Record ID: 372470
The HEK293T cells are maintained in disposable flasks until sufficient cell mass has been generated to fill approximately 40 ten tray cell factories, or TTCFs, then transferred and allowed to adhere to the bottom of the trays. Adherent cells are transfected with multiple plasmids encoding all the genetic material required to assemble the lentiviral vector carrying the functional gene of interest. The transfected HEK293T cells then assemble our lentiviral vectors packaged with the functional gene of interest, which bud off into the cell culture media. The media containing the assembled vectors is harvested, purified, concentrated and formulated prior to freezing for storage. These finished lentiviral vectors are what is ultimately used to transduce the targeted cells isolated from the patient.
â€¢ research, and non-clinical and clinical development purposes; and
â€¢ human and animal gene therapy products.
IPSCIO Record ID: 344487
The Licensor has already granted exploitation rights under the Patents to Third Parties for the production of the enzyme I-SceI, the use of the plasmid pSCM525, and, internal research. Consequently, the term exclusive is understood for the purposes of the present agreement as the Licensor being prohibited from exploiting or having exploited or granting a license or exploitation rights under the Patents to a Third Party in the Field, other than those already granted.
The patent is titled Nucleotide sequence encoding the enzyme I-SceI and the uses thereof.
IPSCIO Record ID: 256218
Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al
Eshhar-NIH patent US 8,211,422, Eshhar et al
Eshhar-NIH pending application [US 13/281,560, Eshhar et al
KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.
IPSCIO Record ID: 203310
Licensor will generate and deliver to Licensee two complete copies of a library consisting of three hundred fifty thousand (350,000) mouse embryonic stem cell clones with Selected Mutations, each identified by DNA sequence of its genomic integration site, the OmniBank II Library. Subject to the terms of this Agreement, Licensor will use Diligent Efforts to generate and deliver the OmniBank II Library in accordance with the schedule set forth in the Development Plan.
Licensor grants to Licensee the non-transferable, non-exclusive right under Licensors rights in the Cre-Lox Patents to use, breed and cross-breed Mutant Mice and Progeny that contain one or more lox sites in their genome (Lox Mice), at the internal research facilities of Licensee, solely for research purposes.
Licensor grants to Licensee a worldwide, non-exclusive right and license to use the Bioinformatics Software, under the copyrights and know-how Controlled by Licensor with respect thereto. Licensee shall have the right under the foregoing license to custom configure the Bioinformatics Software for its internal use.
The Bioinformatics Software means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.
The library, constructed using Licensor's proprietary mouse gene knockout technology, will enable a researcher to develop a mouse that has a specific gene removed or â€œknocked-out.â€ The function of that gene can then be studied by comparing the knockout mouse to a normal mouse. Approximately 99 percent of human genes have a mouse counterpart, and research using this technology may lead to the development of drugs for a wide variety of human and animal diseases, including diabetes and obesity, infectious disease, cancer and heart disease. Institute researchers will have certain rights to utilize Lexiconâ€™s patented gene targeting technologies. In addition, Licensor will equip the Institute with the bioinformatics software required for the management and analysis of data relating to the library.
IPSCIO Record ID: 336357
For the TAL Patent Rights, Licensor grants the right to use the TAL nucleases engineered by Licensor pursuant to this Agreement to Develop Licensee license products until the filing of an IND for each Licensee Licensed Product, in the Field.
Also, for an Exclusive License, Licensor grants an exclusive ( even as to Licensor) license under the TAL Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Licensee Licensed Product in the Field in the Territory.
For the Right of Reference, Licensor grants a Right of Reference, to any data Controlled by Licensor that relates to the Licensed Licensor Intellectual Property, the Agreement CAR-Ts, the Licensee Licensed Products or preclinical studies with respect to the Licensee Licensed Products and that Licensee reasonably believes may be necessary or useful to the Development.
For the License to Licensor Improvements, Licensor grants a nonexclusive, worldwide, sublicensable, perpetual and irrevocable license under any Licensor Improvements that were solely or jointly invented by the employees, agents or independent contractors of Licensee to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes.
Agreement CAR-T means any CAR-T utilizing the Licensor Technology that is identified, created or developed Targeting a Licensee Target.
CAR means a chimeric antigen receptor expressed from an experimentally validated Licensor viral construct with specific molecular architecture and signaling domain sequences.
CAR-T means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using Licensor Technology.
TAL Effector-mediated DNA modification,
Modular DNA binding domains and methods of use, and
Method for treating materials with pulsed electric field, and other patents.
CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patientâ€™s own T-cells to target tumor cells).
The Field means human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes.
The Parties are collaborating to discover and research novel CAR-Ts active against certain designated targets and to provide for Licensee to further research, develop, manufacture and commercialize such CAR-Ts and products containing such CAR-Ts.